View:
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
January 22, 1997
----------------
ENZON, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-12957 22-237286
------------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification)
20 Kingsbridge Road, Piscataway, New Jersey 08854
-------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (908) 980-4500
(Former name or former address, if changed since last report)
Item 5. Other Events
Enzon, Inc. ("Enzon" or the "Company") announced the appointment of Dr.
Jeffrey McGuire to the newly created position of vice president, research and
development and chief scientific officer. Dr. McGuire will be responsible for
the research and clinical functions of the Company. This position was created to
better enable the Company to direct its research and clinical projects.
Dr. McGuire holds a B.S. in Life Sciences from the Massachusetts Institute
of Technology and a Ph.D. in Life Sciences, with a concentration in molecular
biology, from the University of Delaware.
Dr. McGuire served as a research scientist at the Frederick Cancer Research
Center studying anthracycline anti-cancer compounds. Additionally, he conducted
post-doctoral research at Harvard Medical School.
Dr. McGuire was with the Genex Corporation from 1980 until it was acquired
by Enzon in 1991, where he held various research, business development and
management positions.
Since 1991, Dr. McGuire has been responsible for Enzon's Single-Chain
Antigen- Binding (SCA) (registered trademark) protein program and intellectual
property portfolio. In addition, he has served as liaison between Enzon's R&D
and business development activities.
The Company also announced that Dr. Robert Shorr will assume the position
of vice president, science and technology, reporting to Dr. McGuire. Dr. Shorr
will be responsible for identifying new applications for Enzon's proprietary
technologies and evaluating external technologies for potential licensing.
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: January 27, 1997
ENZON, INC.
(Registrant)
By: /S/ KENNETH J. ZUERBLIS
Kenneth J. Zuerblis
Vice President, Finance
and Chief Financial
Officer
- 3 -